Estimation of k and V_D of Aminoglycosides

The elimination rate constant (k) determines how quickly the body removes aminoglycosides, directly influencing dosage timing and frequency. Clinicians use k to calculate appropriate dosing intervals and maintain therapeutic drug concentrations. If k is high, indicating rapid clearance, dosing intervals may need to be shortened to maintain efficacy and prevent subtherapeutic levels.

Volume of distribution (VD) reflects how extensively aminoglycosides disperse into body tissues versus remaining in plasma. A large VD may necessitate higher doses to achieve therapeutic levels in tissue. Understanding VD helps clinicians tailor drug dosing to individual patient needs, considering variations in metabolism and organ function.

Blood samples are collected at specific times: 30 minutes post-infusion to measure peak concentration (Cmax) after the distribution phase completes, and just before the next dose to measure trough concentration (Cmin) during the elimination phase. These samples enable accurate estimation of k and VD using a one-compartment model.

Target peak gentamicin concentrations range from 6–10 μg/mL for severe to life-threatening infections. Lower steady-state trough levels are maintained based on infection severity and compromised renal function. These concentration ranges guide dose determination and ensure therapeutic efficacy while minimizing toxicity risk.

The infusion rate is calculated using three key parameters: the elimination rate constant (k), volume of distribution (VD), and desired peak plasma drug concentration. This calculation ensures aminoglycosides are administered at rates that achieve and maintain therapeutic concentrations while accounting for individual patient clearance and distribution characteristics.

Aminoglycosides are primarily eliminated by the kidneys, so compromised renal function reduces drug clearance and prolongs elimination. Lower trough levels must be maintained in patients with renal impairment to prevent toxic accumulation. Adjusting trough targets based on renal function ensures safe, effective therapy while minimizing nephrotoxicity and ototoxicity risks.

A one-compartment model simplifies pharmacokinetic analysis by avoiding the distributive phase, allowing clinicians to collect minimal plasma samples at specific intervals for accurate k and VD estimation. This approach reduces sampling burden while providing reliable parameters for precise dosing based on desirable peak and trough blood concentrations.